Enanta Pharmaceuticals, Inc. (FRA:9EP)

Enanta Pharmaceuticals Statistics

Total Valuation

FRA:9EP has a market cap or net worth of EUR 351.46 million. The enterprise value is 361.98 million.

Market Cap	351.46M
Enterprise Value	361.98M

Important Dates

The last earnings date was Monday, November 17, 2025.

Earnings Date	Nov 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	28.86M
Shares Outstanding	n/a
Shares Change (YoY)	+0.85%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	4.37%
Owned by Institutions (%)	66.98%
Float	21.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.31
PB Ratio	6.37
P/TBV Ratio	6.37
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-5.19
EV / Sales	6.43
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.20

Financial Position

The company has a current ratio of 4.21, with a Debt / Equity ratio of 3.11.

Current Ratio	4.21
Quick Ratio	4.03
Debt / Equity	3.11
Debt / EBITDA	n/a
Debt / FCF	-6.25
Interest Coverage	-11.11

Financial Efficiency

Return on equity (ROE) is -84.63% and return on invested capital (ROIC) is -17.19%.

Return on Equity (ROE)	-84.63%
Return on Assets (ROA)	-16.23%
Return on Invested Capital (ROIC)	-17.19%
Return on Capital Employed (ROCE)	-36.76%
Revenue Per Employee	463,964
Profits Per Employee	-581,617
Employee Count	120
Asset Turnover	0.20
Inventory Turnover	n/a

Taxes

Income Tax	-1.41M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +46.01% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+46.01%
50-Day Moving Average	9.60
200-Day Moving Average	6.89
Relative Strength Index (RSI)	71.98
Average Volume (20 Days)	3

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.81

Income Statement

In the last 12 months, FRA:9EP had revenue of EUR 55.68 million and -69.79 million in losses. Loss per share was -3.27.

Revenue	55.68M
Gross Profit	55.68M
Operating Income	-72.74M
Pretax Income	-71.21M
Net Income	-69.79M
EBITDA	-68.83M
EBIT	-72.74M
Loss Per Share	-3.27

Balance Sheet

The company has 160.97 million in cash and 171.36 million in debt, giving a net cash position of -10.39 million.

Cash & Cash Equivalents	160.97M
Total Debt	171.36M
Net Cash	-10.39M
Net Cash Per Share	n/a
Equity (Book Value)	55.16M
Book Value Per Share	2.58
Working Capital	132.77M

Cash Flow

In the last 12 months, operating cash flow was -16.43 million and capital expenditures -10.99 million, giving a free cash flow of -27.42 million.

Operating Cash Flow	-16.43M
Capital Expenditures	-10.99M
Free Cash Flow	-27.42M
FCF Per Share	n/a

Margins

Gross margin is 100.00%, with operating and profit margins of -130.65% and -125.36%.

Gross Margin	100.00%
Operating Margin	-130.65%
Pretax Margin	-127.90%
Profit Margin	-125.36%
EBITDA Margin	-123.63%
EBIT Margin	-130.65%
FCF Margin	n/a

Dividends & Yields

FRA:9EP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.85%
Shareholder Yield	-0.85%
Earnings Yield	-19.86%
FCF Yield	-7.80%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:9EP has an Altman Z-Score of -1.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.68
Piotroski F-Score	3